Company: BGLC
Filing Date: 2025-08-18
Form Type: 10-Q
Source: 0001477932-25-006023
Chunk: 37

Company: BioNexus Gene Lab Corp
Filing Date: 2025-08-18
Form: 10-Q
Item: Part I, Item 1
Chunk 37
---
Total    Six month period ended June 2024               REVENUE  $8,661  $4,347,754  $-  $4,356,415                   COST OF REVENUE   (4,605)  (3,698,059)  -   (3,702,664)                  GROSS PROFIT   4,056   649,695   -   653,751                   OTHER INCOME                 Dividend income    -   20,827   -   20,827 Interest income   60,937   17,785   -   78,722 Fair value gain on investments in equity securities   -   173,317   -   173,317 Gain on disposal of investments in equity securities   -   14,298   -   14,298 Reversal of expected credit losses   -   584,415   -   584,415 Others   15,121   45,252   -   60,373 TOTAL OTHER INCOME   76,058   855,894   -   931,952                   OPERATING EXPENSES                 Sales and marketing   (54,116)  (223,699)  (12,550)  (290,365)Research and development   (19,673)  -   -   (19,673)General and administrative   (111,429)  (252,162)  (511,032)  (874,623)Fair value loss on investments in equity securities   -   (100,433)  -   (100,433)Provision for expected credit losses    -   (120,469)  -   (120,469)OPERATING EXPENSES   (185,218)  (696,763)  (523,582)  (1,405,563)                  (LOSS)/PROFIT FROM OPERATIONS   (105,104)  808,826   (523,582)  180,140                   FINANCE COSTS   (4,